phospholamban: Clinical Trials

6 trials of phospholamban, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 3 Phase 3, 2 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Completed 3
Not applicable2Completed 2
Phase 21Completed 1

Follow phospholamban: new trials by email Literature Review of phospholamban trials Research Report on phospholamban

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX - Cocaine Use Disorder
Phase 2CompletedUniversity of Texas Southwestern Medical Center4272023-04-182025-10-21
Comparison of Active Cycle of Breathing Technique and Pursed Lip Breathing With TheraPep
Thera PEP, ACBT and PLB - Chronic Obstructive Pulmonary Disease Exacerbation
Not applicableCompletedUniversity of Jazan402022-12-302023-05-19
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL® - Methamphetamine Use Disorder
Phase 3CompletedUniversity of Texas Southwestern Medical Center4032017-05-052026-10-27
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
Chiglitazar, Placebo - Type 2 Diabetes
Phase 3CompletedChipscreen Biosciences, Ltd.5352014-06-012019-10-25
Selenium Supplementation in Pregnancy
Selenium, Sugar Pill Placebo, Selenium + L-Thyroxine (LT4) - Pregnancy, Infertility
Not applicableCompletedUniversity of Roma La Sapienza562012-04-012018-01-30
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125 - Pulmonary Disease, Chronic Obstructive
Phase 3CompletedGlaxoSmithKline3492011-03-012017-10-11

Conditions studied

Pulmonary Disease, Chronic Obstructive (2)  ·  Abortion, Spontaneous (1)  ·  Cocaine-Related Disorders (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Infertility (1)  ·  Postpartum Thyroiditis (1)  ·  Pre-Eclampsia (1)

Sponsors

University of Texas Southwestern Medical Center (2)  ·  Chipscreen Biosciences, Ltd. (1)  ·  GlaxoSmithKline (1)  ·  University of Jazan (1)  ·  University of Roma La Sapienza (1)

Countries

United States (3)  ·  Bulgaria (1)  ·  China (1)  ·  Estonia (1)  ·  Germany (1)  ·  Italy (1)  ·  Russia (1)  ·  Saudi Arabia (1)  ·  United Kingdom (1)

Top investigators

Madhukar Trivedi, MD (2)  ·  Abu Shaphe (1)  ·  Andrea M Isidori, MD, PhD (1)  ·  Linong Ji, Dr. (1)

Results publications

PMID 33497547, PMID 37245855, PMID 37377462, PMID 38665252, PMID 38856086, PMID 40360074, PMID 40623319, PMID 40767786, PMID 42180350, PMID 42504048

NIH funding

UG1DA020024 (2)